BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3838394)

  • 1. [Prognostic value of the initial remission during chemotherapy of patients with lymphosarcoma].
    Kruglova GV; Abdyldaev RA
    Vopr Onkol; 1985; 31(1):26-32. PubMed ID: 3838394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
    Yong W; Zheng W; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for primary splenic low-grade non-Hodgkin's lymphomas.
    Musteata VG; Corcimaru IT; Iacovleva IA; Musteata LZ; Suharschii IS; Antoci LT
    Clin Lab Haematol; 2004 Dec; 26(6):397-401. PubMed ID: 15595997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
    Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
    Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma].
    Dzhumabaeva BT; Kremenetskaia AM; Gotman LN; Shavlokhov VS; Kaplanskaia IB; Kravchenko SK; Vishnevskaia ES; Gemdzhian EG; Frank GA
    Ter Arkh; 2005; 77(8):78-81. PubMed ID: 16206611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
    Aref A; Narayan S; Tekyi-Mensah S; Varterasian M; Dan M; Eilender D; Karanes C; al-Katib A
    Radiat Oncol Investig; 1999; 7(3):186-91. PubMed ID: 10406061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
    Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.